Global House Dust Mite Allergy Market, By Diagnosis (Skin Prick Test (SPT), Specific IgE Blood Test, Others), Therapy Type (Medication, Immunotherapy, Nasal Irrigation, Others), Route of Administration (Oral, Nasal, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
House Dust Mite Allergy Market Analysis and Size
As per WHO records of all types of respiratory allergies, around 70% allergic reactions are related with house dust mites. The incidence of allergic rhinitis accounts for approximately 10-25%, globally. Additionally, as per the World Health Organization (WHO), in 2020, it was reported that about 70% of allergic reactions are caused because of house dust mite allergen.
Data Bridge Market Research analyses a growth rate in house dust mite allergy market in the forecast period 2023-2030. The expected CAGR of house dust mite allergy market is tend to be around 13% in the mentioned forecast period. The market was valued at USD 1.88 billion in 2022, and it would grow upto USD 5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
House Dust Mite Allergy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Skin Prick Test (SPT), Specific IgE Blood Test, Others), Therapy Type (Medication, Immunotherapy, Nasal Irrigation, Others), Route of Administration (Oral, Nasal, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Shionogi & Co., Ltd (Japan), Stallergenes Greer (Switzerland), Merck & Co., Inc (U.S.), Torii Pharmaceutical Co.,Ltd (Japan), Ergomed plc (U.K.), Allergy Therapeutics (U.K.), DMS Imaging (Belgium), HAL Allergy B.V (Netherlands), Trio Lifescience Private Limited (India), Teva Pharmaceutical Industries Ltd (Israel), ICB PHARMA (Poland), Bayer AG (Germany), Sanofi (France), Catalent, Inc (India), GSK Plc. (U.K.), Merz Pharma (Germany)
|
|
Market Opportunities
|
|
Market Definition
Dust mite allergy is a type of allergic reaction caused by dust mites present in house environments. House dust mites are tiny bugs with a very adaptive habitat and can survive in any climatic condition. Some people with strong immune systems do not respond to these mites, but people affected by these witness symptoms such as hay running nose, cough, fever, and others. Numerous people also experience conditions such as sinus infections, allergy rhinitis, and asthma.
House Dust Mite Allergy Market Dynamics
Drivers
- Increasing Drug Approvals
There are different drug approvals by different drug organizations that are helping in boosting the market growth. For instance, in February 2018, Stallergenes Greer and Shionogi & Co., Ltd. received the marketing approval of Actair. It is an allergy immunotherapy drug used to treat house dust mite (HDM) induced allergic rhinitis in Japan. Stallergenes Greer partnered with Shionogi & Co., Ltd. and announced New Drug Application submission for the drug in January 2017. This approval will provide an effective treatment for house dust mite (HDM) induced allergic rhinitis in Japan and will enlarge the business of both the pharmaceutical companies. Furthermore, Merck & Co., Inc. received the U. S. FDA approval in 2017 for Odactra, an anti-allergy drug used to treat house dust mite-induced nasal inflammation in adults. The drug is widely available in oral dosage form and is administered sublingually. This novel drug will deliver a quality treatment to people suffering from house dust mite induced rhinitis and enlarges the business of the company.
Opportunities
- Growing Demand of Prescription-Based Drugs
The prescription-based drugs increase the market growth resulting in nearly three-fifths of the market, and is expected to maintain its leadership status during the forecast period 2023-2030, due to increase in occurrence of house dust mite allergy diseases and numerous initiatives taken by government and private organizations to spread awareness about different allergic diseases.
Restraints/Challenges
- Side Effects of House dust mite allergy
Drugs of this condition have numerous side effects such as rash, transient fever, edema, and other problems. This hampers the market growth.
- Discontinuation of Drug Trials
The drug development for the disease has faced major obstacles as numerous therapies have failed to demonstrate efficacy or were associated with major toxicity. Thus, this hampers the growth of the market.
This house dust mite allergy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the house dust mite allergy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global House Dust Mite Allergy Market
The outbreak of the Covid-19 pandemic has had an affirmative impact on the house dust mite allergy treatment market, due to the implementation of the global lockdown. All of the people were forced to stay at home for much longer, increasing the exposure to indoor pollutant. This in turn, increased the demand for house dust mite allergy treatment.
Global House Dust Mite Allergy Market Scope
The house dust mite allergy market is segmented on the basis of diagnosis, therapy type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Skin Prick Test (SPT)
- Specific IgE Blood Test
- Others
Therapy Type
- Medication
- Antihistamines
- Corticosteroids
- Leukotriene Modifiers
- Others
- Immunotherapy
- Nasal Irrigation
- Others
Route of Administration
- Oral
- Nasal
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
House Dust Mite Allergy Market Regional Analysis/Insights
The house dust mite allergy market is analyzed and market size insights and trends are provided by diagnosis, therapy type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the house dust mite allergy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for house dust mite allergy market throughout the forecasted period due to surge in incidence of house dust mite allergy diseases, increase in awareness about spreading knowledge regarding allergens, increase in healthcare expenditure, and rising adoption of immunotherapy drugs for the treatment of house dust mite allergies.
North America dominates the market due to increase in occurrence of asthma & allergic rhinitis, growth in number of in-house dust pollution, presence of key players, and development in increase in R&D activities in the pharmaceutical sector in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global House Dust Mite Allergy Market Share Analysis
The house dust mite allergy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to house dust mite allergy market.
Key players operating in the house dust mite allergy market include:
- Shionogi & Co., Ltd (Japan)
- Stallergenes Greer (Switzerland)
- Merck & Co., Inc (U.S.)
- Torii Pharmaceutical Co.,Ltd (Japan)
- Ergomed plc (U.K.)
- Allergy Therapeutics (U.K.)
- DMS Imaging (Belgium)
- HAL Allergy B.V (Netherlands)
- Trio Lifescience Private Limited (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- ICB PHARMA (Poland)
- Bayer AG (Germany)
- Sanofi (France)
- Catalent, Inc (India)
- GSK Plc. (U.K.)
- Merz Pharma (Germany)
SKU-